Enliven Therapeutics, Inc. (ELVN): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$119.36M

Year ended 2025-12-31

-$124.25M

Trailing 12 months to 2026-06-30

2022-12-31 EBITDA (USD) 2025-12-31

Period ended	EBITDA	Change YoY	Source filing
2025-12-31	-$119.36M	n/m	2026-03-03, From 2025-01-01
2024-12-31	-$104.25M	n/m	2026-03-03, From 2024-01-01
2023-12-31	-$83.23M	n/m	2025-03-13, From 2023-01-01
2022-12-31	-$38.59M	n/a	2024-03-14, From 2022-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
Enliven Therapeutics, Inc. (ELVN)	2025-12-31	-$119.36M	n/m
Rhythm Pharmaceuticals, Inc. (RYTM)	2025-12-31	-$191.52M	n/m
Ardelyx, Inc. (ARDX)	2025-12-31	-$37.92M	n/m
Biohaven Ltd. (BHVN)	2025-12-31	-$735.46M	n/m
Rapport Therapeutics, Inc. (RAPP)	2025-12-31	-$124.08M	n/m
Rigel Pharmaceuticals Inc (RIGL)	2025-12-31	$127.88M	+384.0%
BGM Group Ltd. (BGM)	2025-09-30	-$11.12M	n/m
Olema Pharmaceuticals, Inc. (OLMA)	2025-12-31	-$178.21M	n/m
MoonLake Immunotherapeutics (MLTX)	2025-12-31	-$242.22M	n/m

Compare ELVN, RYTM, ARDX, BHVN side by side · Screen every company in Pharmaceutical Preparations ↗